Clinical trial
A Randomized Phase II Study to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan Versus CDK4/6 Inhibitor-based Endocrine Therapy as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype According to Gene Expression Profiling.
NCT06486883 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase II Study to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan Versus CDK4/6 Inhibitor-based Endocrine Therapy as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype According to Gene Expression Profiling.
- Lead sponsor
- MedSIR
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- June 30, 2025
- Completion date
- January 31, 2028
- Enrollment
- 200 (estimated)
- Sites
- 79
Conditions
As the registry lists them; a condition with its own page is linked.
advanced breast cancer, advanced breast carcinoma, hormone receptor positive breast carcinoma